Navigation Links
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
Date:2/23/2009

Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additio
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
6. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
9. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  The Academy ... Food and Drug Administration,s (FDA,s) draft guidance and ... products and biosimilars, to bear a nonproprietary name ... has been seeking a decision from the FDA ... diverse health care stakeholders urging the agency to ...
(Date:8/27/2015)... Aug. 27, 2015  A recent study by ... Journal, compared the Arthrosurface HemiCAP® Wave implant, which ... an "onlay" design implant for isolated patellofemoral disease. ... function and pain scores, none of the patients ... (OA). However, 53% of the patients in the ...
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3DURECT to Participate in Upcoming Healthcare Conferences 2
(Date:8/27/2015)... ... 27, 2015 , ... Keck Graduate Institute (KGI), School of Pharmacy celebrated its ... a formal ceremony recognizing them as members of the 2nd class of the KGI ... Symbolizing dedication to clinical service and patient care, the White Coat Ceremony is held ...
(Date:8/27/2015)... ... 2015 , ... According to an article published August 21st on ... the success of a patient who is attempting to lose weight. Specifically, the trial ... over that period, and compared those results with how helpful each patient felt their ...
(Date:8/27/2015)... ... ... Mesa Community College graduate, Andrew Sypher (Mesa), is one of 10 ... and engagement, to receive a Phi Theta Kappa 2015 Hites Transfer Scholarship, to assist ... a $7,500 scholarship to assist in his goal of becoming a foreign diplomat with ...
(Date:8/27/2015)... ... August 27, 2015 , ... In the addiction treatment industry, some patients go ... relapsing and returning again, all at great cost to them and their families. Others ... or soon after leaving facilities who claim to have given addicts tools to overcome ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to the Rocky ... patient with hemophilia is $175,000. Hemophilia is an inherited, life-long condition with no ... RMHBDA exists to help raise funds for patients suffering from bleeding disorders, deliver ...
Breaking Medicine News(10 mins):Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4Health News:Article on Physician Influence on Weight Loss Highlights the Importance of a Doctor Who Cares, says Dr. Feiz & Associates 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4
... at Monash University in Australia have developed a process for ... without any moving parts, potentially allowing doctors //to do blood ... new method uses the same principle that causes tea leaves ... stirred teacup, a phenomenon first explained by Einstein in the ...
... in a worldwide research have come up with a microbicidal ... is expected to evolve into a powerful new protection weapon ... be 95% efficient. ,Brazilian scientists, who aim ... microbicides , assure the gel will be on the market ...
... cancer death in the U.S.; more than 30,000 Americans are ... ,Pancreatic cancer is an extremely difficult cancer to treat and ... factor in pancreatic cancer is cigarette smoking; other links have ... In a new study, researchers at the Harvard School of ...
... fatal, at the hands of stomach cancer, according to experts. ... rest a mystery of 200 years, // regarding the cause ... recent theory, running since the 1961 discovery of arsenic in ... was due to arsenic poisoning. ,Publishing results in the ...
... care clinics in China have been asked to be ... handle cases. //The Ministry of Health has also requested ... diarrhea cases. ,As Norovirus infections are highly ... in restaurants and hotels. These viruses are one of ...
... one of the most common complaints that physicians face all over ... drugs, such as Oxycontin and Vicodin // are often prescribed to ... finds that these narcotic drugs should only be used to treat ... as it would result in its abuse. ,'Opioids may ...
Cached Medicine News:Health News:Einstein's Tea Leaves Inspire New Blood Separation Technique 2Health News:Link Found Between Periodontal Disease and Pancreatic Cancer 2Health News:Mighty Conqueror Felled by Stomach Cancer 2
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Intermittent catheter...
Medicine Products: